Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab;Eficacia de la premedicación con un esteroide y un antihistamínico en la prevención de reacciones infusionales por infliximab

Gastroenterologia y Hepatologia

Volumn 31, Issue 10, 2008, Pages 629-632

  San José Bermejo, Fernando ^a   San Román, Antonio López ^b   Algaba, Alicia ^a   Van Domselaar, Manuel ^b   Carneros, José A ^a   Rivero, Miguel ^b   Piqueras, Belén ^a   Valer, M Paz ^a  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; CORTICOSTEROID; DEXCHLORPHENIRAMINE; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ALLERGY; ARTICLE; ATOPIC DERMATITIS; CROHN DISEASE; DIAPHORESIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; INDUCED HYPOTENSION; INFUSION REACTION; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NONVERBAL COMMUNICATION; PREMEDICATION; PREVALENCE; PROSPECTIVE STUDY; SIDE EFFECT; SMOKING; TACHYCARDIA; TREATMENT DURATION; ULCERATIVE COLITIS;

EID: 60149106151     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/s0210-5705(08)75809-6     Document Type: Article

References (17)

1. Mayer L, Young Y. Infusion reactions and their management. Gastroenterol Clin North Am. 2006;35:857-66.
2. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;24 Suppl:2-6.
3. Baert F, Noman M, Vermiere S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-8.
4. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9.
5. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003;124:917-24.
6. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusions reactions with to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-24.
7. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther. 2003;17:75-84.
8. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-85.
9. Colombel JF, Loftus EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
10. Maser E, Villela R, Silverberg M, Greenberg G. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-54.
11. Zabana Y, Domenech E, Manosa M, García-Planella E, Marín L, Navarro-Llavat M, et al. Perfil de seguridad de infliximab en la enfermedad inflamatoria intestinal: 7 años de experiencia. Gastroenterol Hepatol. 2007;30:185.
12. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-31.
13. Targan SR, Hanauer SB, Van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-35.
14. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-405.
15. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-9.
16. Mantzaris GJ, Kalantzis C, Koilakou S, Roussos A, Christidou A, Kalogeropoulos J, et al. Similar efficacy of two strategies to prevent secondary loss of response to infliximab, co-administration of azathioprine and pre-treatment with hydrocortisone, on the long term efficacy of infliximab in Crohn's disease. Gut. 2007;56 Suppl 3:24A.
17. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther. 2006;23:451-63.